HomeCompareEQRXW vs NNN

EQRXW vs NNN: Dividend Comparison 2026

EQRXW yields 4395.60% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQRXW wins by $17844003331690.02M in total portfolio value
10 years
EQRXW
EQRXW
● Live price
4395.60%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17844003331690.04M
Annual income
$17,079,643,292,413,290,000.00
Full EQRXW calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — EQRXW vs NNN

📍 EQRXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEQRXWNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EQRXW + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EQRXW pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EQRXW
Annual income on $10K today (after 15% tax)
$373,626.37/yr
After 10yr DRIP, annual income (after tax)
$14,517,696,798,551,296,000.00/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, EQRXW beats the other by $14,517,696,798,551,294,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EQRXW + NNN for your $10,000?

EQRXW: 50%NNN: 50%
100% NNN50/50100% EQRXW
Portfolio after 10yr
$8922001665845.03M
Annual income
$8,539,821,646,206,646,000.00/yr
Blended yield
95.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

EQRXW
No analyst data
Altman Z
9.5
Piotroski
1/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EQRXW buys
0
NNN buys
0
No recent congressional trades found for EQRXW or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEQRXWNNN
Forward yield4395.60%5.68%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$17844003331690.04M$25.6K
Annual income after 10y$17,079,643,292,413,290,000.00$2,637.42
Total dividends collected$17792054110403.60M$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: EQRXW vs NNN ($10,000, DRIP)

YearEQRXW PortfolioEQRXW Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$450,260$439,560.44$10,737$617.02+$439.5KEQRXW
2$18,978,664$18,496,885.68$11,577$710.93+$18.97MEQRXW
3$748,953,345$728,646,173.66$12,538$822.59+$748.94MEQRXW
4$27,674,743,815$26,873,363,736.79$13,645$956.06+$27674.73MEQRXW
5$957,652,835,286$928,040,859,403.20$14,925$1,116.51+$957652.82MEQRXW
6$31,037,578,041,538$30,012,889,507,782.54$16,415$1,310.57+$31037578.03MEQRXW
7$942,293,671,101,243$909,083,462,596,797.50$18,158$1,546.77+$942293671.08MEQRXW
8$26,802,238,424,024,828$25,793,984,195,946,500.00$20,213$1,836.20+$26802238424.00MEQRXW
9$714,355,176,894,161,700$685,676,781,780,455,000.00$22,649$2,193.37+$714355176894.14MEQRXW
10$17,844,003,331,690,041,000$17,079,643,292,413,290,000.00$25,558$2,637.42+$17844003331690.02MEQRXW

EQRXW vs NNN: Complete Analysis 2026

EQRXWStock

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.

Full EQRXW Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this EQRXW vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EQRXW vs SCHDEQRXW vs JEPIEQRXW vs OEQRXW vs KOEQRXW vs MAINEQRXW vs ADCEQRXW vs EPRTEQRXW vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.